)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Mesoblast
Mesoblast (MSB) investor relations material
Mesoblast Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary1 Jun, 2026
Leadership in allogeneic cellular medicines
Global leader in off-the-shelf cellular therapies for severe inflammatory conditions, with operations in the US, Australia, and Singapore.
Product candidates based on remestemcel-L and rexlemestrocel-L stromal cell platforms.
First FDA-approved product, Ryoncil, launched successfully; robust global IP portfolio through at least 2044.
Commercial-scale FDA-inspected manufacturing facilities established.
Commercial performance and financial position
Ryoncil net revenue exceeded US $100M since launch, with Q3 FY26 net revenue at US $30.3M.
Gross profit for 1H FY26 was US $44.2M, supporting reinvestment in R&D and clinical programs.
Cash balance of US $122M as of March 31, 2026; net operating cash spend for Q3 FY26 was US $4.1M.
New US $125M term loan refinanced higher-cost debt, supporting ongoing Phase 3 programs and manufacturing.
Proprietary technology and pipeline
Unique allogeneic cell technology enables scalable, off-the-shelf production with no need for immunosuppression.
Extensive pipeline includes late-stage assets for pediatric/adult SR-aGvHD, chronic low back pain, and heart failure.
Partnerships in Japan, Europe, Latin America, and China expand market reach for key indications.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Mesoblast
- RyoncilⓇ launch drove 191% revenue growth, expanded coverage, and strengthened cash reserves.MSB
H2 20255 Jun 2026 - Ryoncil® revenues hit US$30.3M, cash spend improved, and key clinical milestones were achieved.MSBQ3 202630 Apr 2026
- FDA approval and new capital position the company for commercialization and growth.MSBRegistration filing23 Apr 2026
- Resale of 2,000,000 shares (200,000 ADSs) by a major shareholder, with no proceeds to the company.MSBRegistration filing23 Apr 2026
- Biotech registers 500,000 ADSs for resale; proceeds only if warrants are exercised.MSBRegistration filing23 Apr 2026
- Shareholders may resell ADSs from a recent placement as the company advances cell therapy commercialization.MSBRegistration filing23 Apr 2026
- Resale of 200,000 ADSs by a major shareholder highlights high risk and capital needs.MSBRegistration filing23 Apr 2026
- Blockbuster cell therapy programs advance toward pivotal milestones and commercial expansion.MSBR&D Day 20269 Apr 2026
- Ryoncil/RYONCIL launch drove $49M H1 FY26 revenue, 93% margin, and strong FY26 outlook.MSBH1 20267 Apr 2026
Next Mesoblast earnings date
H2 202627 Aug, 2026
Mesoblast
Next Mesoblast earnings date
H2 202627 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage